Exelixis 3-month delay for cabozantinib data in medullary thryoid cancer
This article was originally published in Scrip
Executive Summary
Exelixis has said that it is extending its timeline to report top-line data from the Phase III EXAM trail of its investigational agent cabozantinib in medullary thyroid cancer (MTC) by about three months, or until the end of the third quarter. Data had been expected by mid-year.